B
OREX

Bailard’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Bailard’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-19,800
Closed -$1.29M – 259
2014
Q1 		$1.29M Sell
19,800
-4,530
-19% -$306K 0.2% 72
2013
Q4 		$1.37M Buy
24,330
+12,000
+97% +$674K 0.22% 69
2013
Q3 		$756K Hold
12,330
– – 0.14% 117
2013
Q2 		$721K Buy
+12,330
New +$759K 0.13% 122

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bailard's OREX Position: Q2 2014 in Review

Bailard sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2014, closing a stake of 19,800 shares — an estimated $1.29M sold.

Bailard first reported a position in OREX in Q2 2013 and held it in 4 quarters. The position peaked at $1.37M in Q4 2013. 129 funds tracked by Wall St. Rank hold OREX as of Q2 2014.

  • Bailard reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • Bailard sold 19,800 Orexigen Therapeutics, Inc. shares in Q2 2014, an estimated $1.29M.
  • Bailard first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 4 quarters.
  • Bailard's Orexigen Therapeutics, Inc. position peaked at $1.37M in Q4 2013.
  • 129 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2014.

Based on Bailard's 13F filing for Q2 2014, filed 30 Jul 2014.